医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Largest Chinese CRO, WuXi PharmaTech, Purchases Multiyear ADMET Predictor License

2013年11月12日 PM10:25
このエントリーをはてなブックマークに追加


 

LANCASTER, Calif.

Simulations Plus, Inc. (NASDAQ: SLP), a leading provider of consulting services and software for pharmaceutical discovery and development, today announced that WuXi PharmaTech (NYSE:WX), China’s largest contract research organization (CRO), has obtained a multiyear license to ADMET Predictor™, Simulations Plus’ flagship structure-to-property prediction software.

John DiBella, vice president of marketing and sales for Simulations Plus, said: “We’re very pleased that WuXi has elected to license the ADMET Predictor Toxicity Module. WuXi offers a variety of in vitro and in vivo services to assist its customers in pharmaceutical research and development. The ADMET Predictor Toxicity Module provides more than 30 different kinds of toxicity predictions, requiring only molecular structures as input. These in silico predictions will provide WuXi with an additional service offering and are expected to assist both in prioritizing which in vitro assays need to be run for particular drugs and by filling in the gaps in in vitro data in support of pre-IND (initial new drug) and IND filings with regulatory agencies for WuXi’s customers. This license is the result of the combined efforts of Simulations Plus and PharmoGo, our distributor in China.”

About Simulations Plus, Inc.

Simulations Plus, Inc., is a premier developer of groundbreaking drug discovery and development simulation software, which is licensed to and used in the conduct of drug research by major pharmaceutical and biotechnology companies worldwide. For more information, visit our Web site at www.simulations-plus.com.

Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995 – With the exception of historical information, the matters discussed in this press release are forward-looking statements that involve a number of risks and uncertainties. Our actual future results could differ significantly from those statements. Factors that could cause or contribute to such differences include, but are not limited to: our ability to maintain our competitive advantages, acceptance of new software products and improved versions of our existing software by our customers, the general economics of the pharmaceutical industry, our ability to finance growth, our ability to continue to attract and retain highly qualified technical staff, and a sustainable market. Further information on our risk factors is contained in our quarterly and annual reports as filed with the U.S. Securities and Exchange Commission.

CONTACT

Simulations Plus Investor Relations
Ms. Renée Bouché, 661-723-7723
renee@simulations-plus.com
or
Hayden
IR
Mr. Cameron Donahue, 651-653-1854
cameron@haydenir.com

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • サラダックス・バイオメディカル、サルバトーレ・J・サラモネ博士が権威ある C.E. Pippenger博士賞を受賞したと発表
  • Japan’s MHLW Approves PADCEV® (enfortumab vedotin) for Advanced Urothelial Cancer
  • VFMCRP announces approval for TAVNEOS® (avacopan) for the treatment of ANCA-associated vasculitis in Japan
  • TAE Life Sciences Announces Installation of First Accelerator-based Neutron Beam System for Biologically Targeted Radiation Therapy at Xiamen Humanity Hospital in China
  • New Study Evaluates the Feasibility of Using Masimo EMMA® Capnography on Mechanically Ventilated Neonates